News & Blog

So You Heard About Rintega? Here’s What’s Next for Brain Tumor Drug Development

Last week, news broke that a promising clinical trial of a new type of treatment for a subset of glioblastoma (GBM) patients – an immunotherapeutic vaccine made by Celldex Therapeutics called RINTEGA (rindopepimut) – was discontinued because patients receiving the investigational therapy were not doing better than patients in the control arm. As we said in our statement regarding […]

The Neuro-Oncology Field Weighs-in: Predictions & Hopes for Brain Tumor Research Advances in 2016

In 2015 we saw a major swing toward positive momentum in the fight against brain tumors, and we’re carrying it into 2016. Last year we experienced the first new treatment for newly diagnosed glioblastoma patients approved to enter the market in nearly a decade, as well as the biggest single-year increase in funding for the […]

One Last Look: Outcomes & Advancements in 2015

Before we completely put 2015 in the rearview, we’d be remiss if we didn’t give a quick review of the progress and impact that we made, together, last year. (Note: NBTS will have a more comprehensive Annual Report later in the year). We’ve already taken a look back at some of our staff’s favorite memories […]

Share